Related Experiment Video

Updated: Feb 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.4K

Direct-acting agents for hepatitis C virus before and after liver transplantation

Yasuhiko Sugawara1, Taizo Hibi1

  • 1Departments of Transplantation/Pediatric Surgery and Gastroenterology and Hepatology, Postgraduate School of Life Science, Kumamoto University.

Bioscience Trends
|December 15, 2017
PubMed

Insights

Chronic hepatitis C virus (HCV) infection is a major health issue, but direct-acting antiviral agents (DAAs) now offer a cure. This review covers DAA treatment for patients who have received or are awaiting liver transplants.

Area of Science:

  • Hepatology
  • Virology
  • Transplantation Medicine

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant global health problem.
  • HCV is a primary reason for liver transplantation worldwide.
  • Direct-acting antiviral agents (DAAs) have transformed HCV into a curable disease.

Purpose of the Study:

  • To review current data on direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) in liver transplant recipients.
  • To summarize the efficacy and safety of DAAs in this specific patient population.

Main Methods:

  • Literature review of studies on DAA treatment in liver transplant recipients.
  • Analysis of available data regarding treatment initiation before or after liver transplantation.

Main Results:

  • DAA therapy is effective in treating HCV in liver transplant recipients.
  • Treatment can be successfully administered both pre- and post-transplant.

Conclusions:

  • Direct-acting antiviral agents represent a breakthrough in managing HCV in liver transplant recipients.
  • DAA treatment offers a curative option, improving outcomes for patients with HCV undergoing or awaiting liver transplantation.

Keywords:
Liver transplantationhepatocellular carcinomaliving donor

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
257
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212